| [1] |
|
| [2] |
Hebert JF, Burfeind KG, Malinoski D, et al. Molecular mechanisms of rhabdomyolysis-induced kidney injury: from bench to bedside[J]. Kidney Int Rep, 2023, 8(1): 17-29. DOI: 10.1016/j.ekir.2022.09.026.
|
| [3] |
Burgess S. Rhabdomyolysis: an evidence-based approach[J]. J Intensive Care Soc, 2022, 23(4): 513-517. DOI: 10.1177/17511437211050782.
|
| [4] |
|
| [5] |
Moinuddin IA. Suspected levetiracetam-induced rhabdomyolysis: A case report and literature review[J]. Am J Case Rep, 2020, 21: e926064. DOI: 10.12659/ajcr.926064.
|
| [6] |
|
| [7] |
Huerta-Alardín AL, Varon J, Marik PE. Bench-to-bedside review: rhabdomyolysis--an overview for clinicians[J]. Crit Care, 2005, 9(2): 158-169. DOI: 10.1186/cc2978.
|
| [8] |
Torres PA, Helmstetter JA, Kaye AM, et al. Rhabdomyolysis: Pathogenesis, diagnosis, and treatment[J]. Ochsner J, 2015, 15(1): 58-69.
|
| [9] |
|
| [10] |
|
| [11] |
Kodama K, Imai T, Kuwana T, et al. Two cases of levetiracetam-induced rhabdomyolysis with low levetiracetam blood concentrations [J]. Cureus, 2025, 17(3): e80877. DOI: 10.7759/cureus.80877.
|
| [12] |
|
| [13] |
Siniscalchi A, Mintzer S, De Sarro G, et al. Myotoxicity induced by antiepileptic drugs: could be a rare but serious adverse event?[J]. Psychopharmacol Bull, 2021, 51(4): 105-116. DOI: 10.64719/pb.4421.
|
| [14] |
|